tetano
Editor, Senior Moderator
Infect Dis Clin North Am
. 2024 Mar;38(1):213-228.
doi: 10.1016/j.idc.2023.12.007. Coronavirus Disease-2019 in the Immunocompromised Host
Christopher D Bertini Jr[SUP] 1 [/SUP], Fareed Khawaja[SUP] 2 [/SUP], Ajay Sheshadri[SUP] 3 [/SUP]
Affiliations
Immunocompromised hosts, which encompass a diverse population of persons with malignancies, human immunodeficiency virus disease, solid organ, and hematologic transplants, autoimmune diseases, and primary immunodeficiencies, bear a significant burden of the morbidity and mortality due to coronavirus disease-2019 (COVID-19). Immunocompromised patients who develop COVID-19 have a more severe illness, higher hospitalization rates, and higher mortality rates than immunocompetent patients. There are no well-defined treatment strategies that are specific to immunocompromised patients and vaccines, monoclonal antibodies, and convalescent plasma are variably effective. This review focuses on the specific impact of COVID-19 in immunocompromised patients and the gaps in knowledge that require further study.
Keywords: COVID-19; Hematologic malignancy; Immunocompromised host; Immunosuppression; Pneumonia; SARS-CoV-2.
. 2024 Mar;38(1):213-228.
doi: 10.1016/j.idc.2023.12.007. Coronavirus Disease-2019 in the Immunocompromised Host
Christopher D Bertini Jr[SUP] 1 [/SUP], Fareed Khawaja[SUP] 2 [/SUP], Ajay Sheshadri[SUP] 3 [/SUP]
Affiliations
- PMID: 38280765
- DOI: 10.1016/j.idc.2023.12.007
Immunocompromised hosts, which encompass a diverse population of persons with malignancies, human immunodeficiency virus disease, solid organ, and hematologic transplants, autoimmune diseases, and primary immunodeficiencies, bear a significant burden of the morbidity and mortality due to coronavirus disease-2019 (COVID-19). Immunocompromised patients who develop COVID-19 have a more severe illness, higher hospitalization rates, and higher mortality rates than immunocompetent patients. There are no well-defined treatment strategies that are specific to immunocompromised patients and vaccines, monoclonal antibodies, and convalescent plasma are variably effective. This review focuses on the specific impact of COVID-19 in immunocompromised patients and the gaps in knowledge that require further study.
Keywords: COVID-19; Hematologic malignancy; Immunocompromised host; Immunosuppression; Pneumonia; SARS-CoV-2.